|
LIVER
Monoclonal Antibody Therapy with Avastin
NCI 5611: Phase I/II trial of bevacizumab (Avastin) in patients with hepatocellular cancer. Bevacizumab is a humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF), a key promoter of the blood-vessel development that is essential to the growth of tumors.
Consortium study.
Sponsor: National Cancer Institute
Comparing Chemotherapies
Phase-III randomized, controlled study comparing the survival of patients with unresectable hepatocellular carcinoma treated with Thymitaq to patients treated with doxorubicin.
Sponsor: Eximias Pharmaceutical Corporation
Principal Investigator: Dr. Scott Wadler
0702-332
Thalidomide for Chemoembolization
NCI 99: A phase-II trial of chronic thalidomide administration in patients undergoing chemoembolization for unresectable hepatocellular carcinoma. Chemoembolization is a treatment to block blood circulation to liver tumors while infusing anti-cancer drugs (in this trial doxorubicin) directly to the tumors. The study tests whether administration of oral thalidomide before and after chemoembolization leads to improved patient outcomes.
Consortium study: NYU-99-37 (open), Mt. Sinai (open), Weill Cornell (open)
Sponsor: National Cancer Institute
0702-36
|
